Operator

Good afternoon, and welcome to the Candel Therapeutics conference call, where the company will be discussing extended follow-up data from the Phase III clinical trial in patients with localized prostate cancer following an oral plenary presentation at the 2026 American Urological Association Annual Meeting with subsequent Q&A from Candel management and their guests, thought leader physicians.

[Operator Instructions]

Please be advised that this call is being recorded. You can find information on a replay of the call and further information related to today's announcements on the Candel Therapeutics website at candeltx.com.

At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations and Business Development at Candel Therapeutics. Mr. Jenkins, please go ahead.

Ted Jenkins

Thank you, operator. Good afternoon, everyone, and thank you for joining us on today's call. Earlier today, the company presented extended follow-up data from the Phase III clinical trial in patients with intermediate to high-risk localized prostate cancer during an oral plenary presentation at the 2026 American Urological Association Annual Meeting in Washington, D.C. We are pleased to conduct a public